Atomo Diagnostics Limited Stock

Equities

AT1

AU0000080327

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 09:58:58 2024-05-12 pm EDT 5-day change 1st Jan Change
0.0275 AUD +1.85% Intraday chart for Atomo Diagnostics Limited -11.29% +25.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 12.34M 8.15M Sales 2023 2.54M 1.68M Capitalization 12.56M 8.3M
Net income 2022 -5M -3.3M Net income 2023 -9M -5.95M EV / Sales 2022 1.57 x
Net cash position 2022 12.63M 8.34M Net cash position 2023 6.22M 4.11M EV / Sales 2023 2.49 x
P/E ratio 2022
-5.58 x
P/E ratio 2023
-1.26 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 60.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.85%
1 week-11.29%
Current month-14.06%
1 month-8.33%
3 months-5.17%
6 months+25.00%
Current year+25.00%
More quotes
1 week
0.03
Extreme 0.027
0.03
1 month
0.03
Extreme 0.027
0.04
Current year
0.02
Extreme 0.022
0.06
1 year
0.02
Extreme 0.02
0.10
3 years
0.02
Extreme 0.02
0.37
5 years
0.02
Extreme 0.02
0.63
10 years
0.02
Extreme 0.02
0.63
More quotes
Managers TitleAgeSince
Founder - 09-12-31
Chief Operating Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member - 22-11-14
Director/Board Member 71 21-10-14
Director/Board Member 66 -
More insiders
Date Price Change Volume
24-05-12 0.0275 +1.85% 264 667
24-05-10 0.027 -3.57% 599,517
24-05-09 0.028 -6.67% 226,945
24-05-08 0.03 0.00% 344,747
24-05-07 0.03 -3.23% 236,112

Delayed Quote Australian S.E., May 12, 2024 at 09:58 pm EDT

More quotes
Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation and female health. Its products include Atomo HIV Self-Test, AtomoRapid HIV (1&2) and ATOMONOW Pregnancy Test. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. Its AtomoRapid HIV (1&2) integrates multiple test components into the device platform. AtomoRapid HIV (1&2) needs a small drop of blood to give results in 15 minutes.
More about the company

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW